<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024724</url>
  </required_header>
  <id_info>
    <org_study_id>STU00083918</org_study_id>
    <secondary_id>STU00083918</secondary_id>
    <nct_id>NCT02024724</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain</brief_title>
  <official_title>Phase 4 Study Comparing of Dexamethasone to Triamcinolone for Ultrasound-guided Trigeminal Nerve Block: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trigeminal neuralgia is a craniofacial pain syndrome that is typically characterized by
      unilateral severe, recurrent, electrical pain in one or more distributions of the trigeminal
      nerve. Current treatment strategies include oral medications as first line therapy with
      surgical interventions reserved for those patients who are refractory to medications or
      unable to tolerate medication side effects. Despite these current treatment options, many
      patients continue to have symptoms. Ultrasound-guided trigeminal nerve block allows for fine
      adjustment of the needle tip and direct observation of the medicine.

      Local anesthetic and steroids have been successfully used for diagnostic and or therapeutic
      nerve pain with great success. Steroids can be short or long acting in duration with varying
      side effects. If there exists a difference in duration of action, using the longer acting
      drug will provide a greater period of symptom relief for the patient and may allow the
      patient to undergo fewer interventional procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects reporting at least 50% overall pain relief</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>block satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Typical Facial Pain</condition>
  <condition>Atypical Facial Pain</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>4 mL of 0.25% bupivacaine</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_label>Triamcinolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>40 mg of Triamcinolone</description>
    <arm_group_label>Triamcinolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>4 mg of Dexamethasone</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting to the Northwestern Pain Center who are eligible and
             scheduled to receive a ultrasound-guided trigeminal nerve block.

        Exclusion Criteria:

          -  Exclusion is the same for patients who are not eligible for ultrasound guided nerve
             blocks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoun Nader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University, Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Kendall, MD</last_name>
    <phone>312-695-2528</phone>
    <email>m-kendall@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anesthesiology Pain Medcine Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kendall, MD</last_name>
      <email>m-kendall@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Antoun Nader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Antoun Nader</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
